Cytosorbents Cor (CTSO) 0.2400 $CTSO
First Publication Using CytoSorb® Therapy During Cardiac Surgery
PR Newswire - Thu Jul 17, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany.
CytoSorbents Consolidates SEC and International Legal Counsel with DLA Piper
PR Newswire - Wed Jul 09, 7:30AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses, announced consolidation of its SEC and international legal counsel with the global law firm, DLA Piper LLP. DLA Piper is one of the largest international business law firms with offices in major markets around the world and legal expertise across a broad range of areas including corporate and finance, litigation and arbitration, Sarbanes Oxley compliance, government affairs, labor law, intellectual property and technology, and tax.
Eagle Pharmaceuticals (EGRX) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:21AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Merriman Capital Initiates Research Coverage on CytoSorbents Corporation
Thomson Reuters ONE - Thu Jun 19, 8:33AM CDT
SAN FRANCISCO - June 19, 2014 - Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of CytoSorbents Corporation (OTCQB: CTSO) with a Buy rating.
Cardica Inc. (CRDC) Soars: Stock Adds 10.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 8:21AM CDT
Cardica Inc. (CRDC) was a big mover last session, as the company saw its shares rise by over 10% on the day.
Vista Partners Publishes June 2014 Macroeconomic & Investment Newsletter
Marketwire - Thu Jun 05, 1:48AM CDT
Vista Partners ("Vista" published its FREE Macroeconomic & Investment Monthly Newsletter for the month of June. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
Oracle Hits New Yearly High; Cytosorbents Posts Record Q4 in 2013
ACCESSWIRE - Tue Apr 01, 12:57AM CDT
Oracle Corporation (NYSE: ORCL) - For an in-depth report on Oracle Corporation follow: www.BullTrends.com/stockquote/ORCL
CytoSorbents Posts Record Q4 2013 and Full Year 2013 Revenue
PR Newswire - Mon Mar 31, 3:05PM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, provides an operational summary and financial results for the fiscal year ending December 31, 2013.
CytoSorbents to Report Fiscal 2013 Operating and Financial Results
PR Newswire - Tue Mar 25, 6:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report fiscal 2013 financial results after the market close on Monday, March 31, 2014.
CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014
PR Newswire - Thu Mar 13, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, announced that it will sponsor a research symposium entitled:
CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering
PR Newswire - Fri Mar 07, 8:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a Nevada corporation, today announced that it has entered into subscription agreements with certain institutional investors to sell approximately $10,200,000 of its common stock and warrants to purchase common stock in a registered direct offering.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista" announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary.
National Institutes of Health Grant Urges Latino Males to Receive Free Confidential HIV Testing
PR Newswire - Wed Jan 29, 7:30AM CST
Today marks the launch of "Conoces a Pepe? Have you met Pepe?," a social impact campaign focusing on educating and mobilizing Hispanic/Latino communities to live their best life with HIV testing and taking responsibility for their health.
Stryker Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 9:20AM CST
Shares of Stryker Corporation were favorably affected by its announcement of acquiring Irvine, Calif.-based Patient Safety Technologies
CytoSorbents to Exhibit at the 43rd Society of Critical Care Medicine Congress and Present at the Biotech Showcase 2014
Marketwire - Tue Jan 07, 8:01AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care immunotherapy company, announced that it will exhibit its CytoSorb(R) and HemoDefend(TM) technologies at the Society of Critical Care Medicine (SCCM) 43rd Critical Care Congress from January 10-12, 2014 at the Moscone Center South in San Francisco, California in Booth 918. More than 4,000 critical care clinicians from the U.S. and abroad are expected to attend.
CytoSorbents Reports on Successful DIVI 2013 Conference
Marketwire - Mon Dec 16, 7:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, reports on its recent activities at the DIVI 2013 Congress in Leipzig, Germany.
Biocon Partners With CytoSorbents to Market CytoSorb(R) -- A 'First-in-Class' Therapy for Sepsis Management
Marketwire - Fri Sep 13, 7:01AM CDT
Biocon Ltd, Asia's largest biotech company, and CytoSorbents Corporation (OTCQB: CTSO), based in the United States, announced today, World Sepsis Day, that they have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb(R), a novel therapy for the management of sepsis.
Stop Sepsis. Save Lives. CytoSorbents Sponsors Global Sepsis Alliance and Sepsis Heroes in Honor of World Sepsis Day
Marketwire - Thu Sep 12, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a leading innovator in the use of blood purification to treat critical illnesses such as sepsis, is a proud sponsor of both the Global Sepsis Alliance and the Sepsis Heroes event hosted by the Sepsis Alliance tonight in New York City, in honor of the second annual World Sepsis Day tomorrow.
CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for HemoDefend(TM)
Marketwire - Mon Sep 09, 11:45AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company specializing in blood purification, announced today that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded the Company a Phase I SBIR (Small Business Innovation Research) contract to further advance its HemoDefend(TM) blood purification technology for packed red blood cell (pRBC) transfusions. The project, entitled "Elimination of blood contaminants from pRBCs using HemoDefend hemocompatible porous polymer beads," is valued at $203,351 over 6 months, with funding to start immediately.
CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment Conference
Marketwire - Wed Aug 28, 8:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, President and Chief Executive Officer, Dr. Phillip Chan will present at the Rodman & Renshaw Annual Global Investment Conference taking place on September 8-10 in New York City.
First Publication Using CytoSorb® Therapy During Cardiac Surgery
PR Newswire - Thu Jul 17, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its CytoSorb® cytokine adsorber in multiple countries worldwide, announced the PDF availability of the first publication describing the use of CytoSorb® intra-operatively during cardiac surgery at the Ludwig Maximilian University of Munich Hospital - Grosshadern Campus, in Germany.
CytoSorbents Consolidates SEC and International Legal Counsel with DLA Piper
PR Newswire - Wed Jul 09, 7:30AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses, announced consolidation of its SEC and international legal counsel with the global law firm, DLA Piper LLP. DLA Piper is one of the largest international business law firms with offices in major markets around the world and legal expertise across a broad range of areas including corporate and finance, litigation and arbitration, Sarbanes Oxley compliance, government affairs, labor law, intellectual property and technology, and tax.
Eagle Pharmaceuticals (EGRX) in Focus: Stock Moves 5.6% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jul 01, 8:21AM CDT
Eagle Pharmaceuticals Inc. (EGRX) was a big mover last session, as the company saw its shares rise by roughly 6% on the day.
Merriman Capital Initiates Research Coverage on CytoSorbents Corporation
Thomson Reuters ONE - Thu Jun 19, 8:33AM CDT
SAN FRANCISCO - June 19, 2014 - Merriman Capital, Inc. ("Merriman"
, a wholly owned subsidiary of Merriman Holdings, Inc. (OTCQX: MERR), announced that it has initiated equity research coverage of CytoSorbents Corporation (OTCQB: CTSO) with a Buy rating. Cardica Inc. (CRDC) Soars: Stock Adds 10.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Jun 18, 8:21AM CDT
Cardica Inc. (CRDC) was a big mover last session, as the company saw its shares rise by over 10% on the day.
Vista Partners Publishes June 2014 Macroeconomic & Investment Newsletter
Marketwire - Thu Jun 05, 1:48AM CDT
Vista Partners ("Vista"
published its FREE Macroeconomic & Investment Monthly Newsletter for the month of June. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. Oracle Hits New Yearly High; Cytosorbents Posts Record Q4 in 2013
ACCESSWIRE - Tue Apr 01, 12:57AM CDT
Oracle Corporation (NYSE: ORCL) - For an in-depth report on Oracle Corporation follow: www.BullTrends.com/stockquote/ORCL
CytoSorbents Posts Record Q4 2013 and Full Year 2013 Revenue
PR Newswire - Mon Mar 31, 3:05PM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, provides an operational summary and financial results for the fiscal year ending December 31, 2013.
CytoSorbents to Report Fiscal 2013 Operating and Financial Results
PR Newswire - Tue Mar 25, 6:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company commercializing its European Union approved CytoSorb® blood filter to treat life-threatening illnesses in the intensive care unit, will report fiscal 2013 financial results after the market close on Monday, March 31, 2014.
CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014
PR Newswire - Thu Mar 13, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, announced that it will sponsor a research symposium entitled:
CytoSorbents Corporation Announces $10,200,000 Registered Direct Offering
PR Newswire - Fri Mar 07, 8:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a Nevada corporation, today announced that it has entered into subscription agreements with certain institutional investors to sell approximately $10,200,000 of its common stock and warrants to purchase common stock in a registered direct offering.
Vista Partners Publishes March 2014 Macroeconomic & Investment Newsletter
Marketwire - Fri Mar 07, 8:00AM CST
Vista Partners ("Vista"
announced today that it published its FREE Macroeconomic & Investment Monthly Newsletter for the month of March. Each monthly newsletter from Vista contains macroeconomic thoughts from Principal Analyst Ross Silver, investment considerations, monthly highlights of each covered company and other broad based commentary. National Institutes of Health Grant Urges Latino Males to Receive Free Confidential HIV Testing
PR Newswire - Wed Jan 29, 7:30AM CST
Today marks the launch of "Conoces a Pepe? Have you met Pepe?," a social impact campaign focusing on educating and mobilizing Hispanic/Latino communities to live their best life with HIV testing and taking responsibility for their health.
Stryker Hits 52-Week High - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 07, 9:20AM CST
Shares of Stryker Corporation were favorably affected by its announcement of acquiring Irvine, Calif.-based Patient Safety Technologies
CytoSorbents to Exhibit at the 43rd Society of Critical Care Medicine Congress and Present at the Biotech Showcase 2014
Marketwire - Tue Jan 07, 8:01AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care immunotherapy company, announced that it will exhibit its CytoSorb(R) and HemoDefend(TM) technologies at the Society of Critical Care Medicine (SCCM) 43rd Critical Care Congress from January 10-12, 2014 at the Moscone Center South in San Francisco, California in Booth 918. More than 4,000 critical care clinicians from the U.S. and abroad are expected to attend.
CytoSorbents Reports on Successful DIVI 2013 Conference
Marketwire - Mon Dec 16, 7:31AM CST
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, reports on its recent activities at the DIVI 2013 Congress in Leipzig, Germany.
Biocon Partners With CytoSorbents to Market CytoSorb(R) -- A 'First-in-Class' Therapy for Sepsis Management
Marketwire - Fri Sep 13, 7:01AM CDT
Biocon Ltd, Asia's largest biotech company, and CytoSorbents Corporation (OTCQB: CTSO), based in the United States, announced today, World Sepsis Day, that they have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb(R), a novel therapy for the management of sepsis.
Stop Sepsis. Save Lives. CytoSorbents Sponsors Global Sepsis Alliance and Sepsis Heroes in Honor of World Sepsis Day
Marketwire - Thu Sep 12, 5:00AM CDT
CytoSorbents Corporation (OTCQB: CTSO), a leading innovator in the use of blood purification to treat critical illnesses such as sepsis, is a proud sponsor of both the Global Sepsis Alliance and the Sepsis Heroes event hosted by the Sepsis Alliance tonight in New York City, in honor of the second annual World Sepsis Day tomorrow.
CytoSorbents Awarded $203K Phase I SBIR Contract from NHLBI/NIH for HemoDefend(TM)
Marketwire - Mon Sep 09, 11:45AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company specializing in blood purification, announced today that the National Heart, Lung, and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), awarded the Company a Phase I SBIR (Small Business Innovation Research) contract to further advance its HemoDefend(TM) blood purification technology for packed red blood cell (pRBC) transfusions. The project, entitled "Elimination of blood contaminants from pRBCs using HemoDefend hemocompatible porous polymer beads," is valued at $203,351 over 6 months, with funding to start immediately.
CytoSorbents to Present at the Rodman & Renshaw Annual Global Investment Conference
Marketwire - Wed Aug 28, 8:00AM CDT
CytoSorbents Corporation (OTCBB: CTSO), a critical care focused company commercializing its European Union approved CytoSorb(R) blood filter to treat life-threatening illnesses in the intensive care unit, President and Chief Executive Officer, Dr. Phillip Chan will present at the Rodman & Renshaw Annual Global Investment Conference taking place on September 8-10 in New York City.
